5-苯基-6-氮杂尿嘧啶 | 23891-08-9

• 物质功能分类: 医药中间体 - 杂环化合物 - 嘧啶类化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 三嗪类
• 中文名称: 5-苯基-6-氮杂尿嘧啶
• 英文名称: 5-phenyl-6-azauracil
• 英文别名: 6-phenyl-1,2,4-triazine-3,5-dione；6-Phenyl-2,3,4,5-tetrahydro-as-triazin-3,5-dion；6-Phenyl-2H,4H-asymm.-triazin-dion-(3,5)；6-Phenyl-as-triazin-3,5(2H,4H)-dion；6-phenyl-2H-1,2,4-triazine-3,5-dione
• CAS: 23891-08-9
• 化学式: C₉H₇N₃O₂
• mdl: MFCD01183870
• 分子量: 189.173
• InChiKey: QDVLVVJHFWNNJK-UHFFFAOYSA-N

物化性质

• 熔点：
  261-261 °C(Solv: 1,4-dioxane (123-91-1); water (7732-18-5))
• 密度：
  1.46±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.7
• 重原子数：
  14
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  70.6
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  5-苯基-6-氮杂尿嘧啶 在 盐酸 、 sodium nitrite 作用下， 反应 2.0h， 以63%的产率得到4-nitroso-6-phenyl-1,2,4-triazine-3,5-dione
  参考文献：
  名称：

  制备一些取代的1,2,4-三嗪

  摘要：

  DOI：

  10.1007/bf00515004
• 作为产物：
  描述：

  Phenylglyoxylsaeure-semicarbazon 在 sodium 作用下， 以 乙醇 、 水 、 乙二醇 为溶剂， 以85%的产率得到5-苯基-6-氮杂尿嘧啶
  参考文献：
  名称：

  Gonadotropin-releasing hormone receptor antagonists and methods relating thereto

  摘要：

  本发明披露了GnRH受体拮抗剂，其在治疗男性和女性的各种性激素相关疾病方面具有用途。本发明的化合物具有以下结构：其中R1、R2、R3a、R3b、R4、R5和n的定义如本文所述，包括立体异构体、前药和其药学上可接受的盐。此外，本发明还披露了含有本发明化合物与药学上可接受的载体结合的组合物，以及与拮抗性促性腺激素释放激素有关的使用方法，用于需要这种方法的受体。

  公开号：

  US20030114455A1

文献信息

• [EN] AZABICYCLO [3. 1. 0] HEXYL DERIVATIVES AS MODULATORS OF DOPAMINE D3 RECEPTORS<br/>[FR] NOUVEAUX COMPOSÉS
  申请人：GLAXO GROUP LTD

  公开号：WO2009043884A1

  公开（公告）日：2009-04-09

  The present invention relates to novel compounds of formula (I) or a salt thereof, wherein G is selected from a group consisting of: phenyl, a 5- or 6-membered monocyclic heteroaryl group, or a 8- to 11-membered heteroaryl bicyclic group; p is an integer ranging from 0 to 5; R1 is halogen, hydroxy, cyano, C1-4alkyl, haloC1-4alkyl, C1-4alkoxy, haloC1-4alkoxy, C1-4alkanoyl and SF5; or corresponds to a group R6; and when p is an integer ranging from 2 to 5, each R1 may be the same or different; R2 is hydrogen or C1-4alkyl; n is 3, 4, 5 or 6; R6 is a moiety selected from the group consisting of: isoxazolyl, -CH2-N-pyrrolyl, 1,1-dioxido-2-isothiazolidinyl, thienyl, thiazolyl, pyridyl, 2-pyrrolidinonyl, and such R6 group is optionally substituted by one or two substituents selected from: halogen, cyano, C1-4alkyl, haloC1-4alkyl, C1-4alkoxy, C1-4alkanoyl; R4 is selected in the group consisting of: hydrogen, halogen, hydroxy, cyano, C1-4alkyl, C3-7 cycloalkyl, haloC1-4alkyl, C1-4alkoxy, haloC1-4alkoxy, C1-4alkanoyl and NR'R'; or R4 is a phenyl group, a 5-14 membered heterocyclic group; and any of such phenyl or heterocyclic group is optionally substituted by 1, 2, 3 or 4 substituents selected from the group consisting of: halogen, cyano, C1-4alkyl, haloC1-4alkyl, C1-4alkoxy, C1-4alkanoyl, haloC1-4alkoxy and SF5; R7 is hydrogen or C1-2alkyl; R' is H, C1-4 alkyl or C1-4 alkanoyl; R' is defined as R'; R' and R' taken together with the interconnecting nitrogen atom may form a 5-, 6-membered saturated or unsaturated heterocyclic ring; processes for their preparation, intermediates used in these processes, pharmaceutical compositions containing them and their use in therapy, as modulators of dopamine D3 receptors, e.g. to treat drug dependency, as antipsychotic agents, to treat obsessive compulsive spectrum disorders, or premature ejaculation.

  本发明涉及式(I)的新化合物或其盐，其中G选自以下组成的一组：苯基，5-或6-成员单环杂环基，或8-至11-成员杂环双环基；p是一个从0到5的整数；R1是卤素，羟基，氰基，C1-4烷基，卤代C1-4烷基，C1-4烷氧基，卤代C1-4烷氧基，C1-4烷酰基和SF5；或对应于一个R6基团；当p是一个从2到5的整数时，每个R1可以相同也可以不同；R2是氢或C1-4烷基；n是3、4、5或6；R6是从以下组成的基团中选择的一个：异噁唑基，-CH2-N-吡咯基，1,1-二氧化-2-异噻唑啉基，噻吩基，噻唑基，吡啶基，2-吡咯烷基，以及这样的R6基团可以选择地被来自以下组成的一个或两个取代基取代：卤素，氰基，C1-4烷基，卤代C1-4烷基，C1-4烷氧基，C1-4烷酰基；R4在以下组成的基团中选择：氢，卤素，羟基，氰基，C1-4烷基，C3-7环烷基，卤代C1-4烷基，C1-4烷氧基，卤代C1-4烷氧基，C1-4烷酰基和NR'R'；或R4是一个苯基，一个5-14成员杂环基；和任何这样的苯基或杂环基可以选择地被来自以下组成的1、2、3或4个取代基取代：卤素，氰基，C1-4烷基，卤代C1-4烷基，C1-4烷氧基，C1-4烷酰基，卤代C1-4烷氧基和SF5；R7是氢或C1-2烷基；R'是H，C1-4烷基或C1-4烷酰基；R'被定义为R'；R'和R'连同相互连接的氮原子可以形成一个5-、6-成员饱和或不饱和杂环环；它们的制备方法，用于这些方法的中间体，含有它们的药物组合物以及它们在治疗中的用途，作为多巴胺D3受体调节剂，例如用于治疗药物依赖，作为抗精神病药物，用于治疗强迫症谱系障碍，或早泄。
• 3-oxo-2(H)-1,2,4-triazine derivatives as ligands of 5 HT1A receptors
  申请人：Pierre Fabre Medicament

  公开号：US06303603B1

  公开（公告）日：2001-10-16

  The invention concerns novel 3-oxo-(2H)-1,2,4-triazine derivatives of general formula (I) in which R1 represents: hydrogen, when A is an optionally substituted nitrogen atom; a linear or branched 1-C4 alkyl group; a C1-C4phenyl alkyl group, the phenyl ring being optionally substituted by one or several groups such as C1-C4 alkyl, C1-C3 alkoxy, halogen, trifluoromethyl. R2 represents: hydrogen; a linear or branched C1-C4 alkyl radical; a C1-C4 phenyl or phenylalkyl group, the phenyl ring being optionally substituted by one or several groups such as C1-C4 alkyl, C1-C3 alkoxy, halogen, trifluoromethyl. A represents an oxygen atom or a nitrogen atom optionally NR3 substituted. R3 represents hydrogen or a methyl group. B represents a group such as (IIa) in which Ar itself represents an aromatic structure such as phenyl, pyridyl or pyrimidyl, optionally substituted by one or several groups such as C1-C3 alkyl, C1-C3 alkoxy, hydroxy, trifluoromethyl or halogen and n can be whole numbers ranging between 3 and 5; (IIb) in which Ar is as defined in formula (IIa) and m can be a whole number ranging between 1 and 2; (IIc) in which R4 represents hydrogen or a C1-C3 alkyl group and n can be whole numbers ranging between 3 and 5.

  本发明涉及通式(I)的新型3-氧代-(2H)-1,2,4-三嗪衍生物，其中R1代表：当A为可选择性取代的氮原子时，氢；线性或支链的C1-C4烷基；C1-C4苯基烷基，苯环可选择性地被一个或多个如C1-C4烷基、C1-C3烷氧基、卤素、三氟甲基的基团取代。R2代表：氢；线性或支链的C1-C4烷基；C1-C4苯基或苯基烷基，苯环可选择性地被一个或多个如C1-C4烷基、C1-C3烷氧基、卤素、三氟甲基的基团取代。A代表氧原子或可选择性NR3取代的氮原子。R3代表氢或甲基。B代表如(IIa)的基团，其中Ar本身代表如苯基、吡啶基或嘧啶基的芳香结构，可选择性地被一个或多个如C1-C3烷基、C1-C3烷氧基、羟基、三氟甲基或卤素的基团取代，n可以是3至5的整数；(IIb)中Ar的定义同(IIa)，m可以是1至2的整数；(IIc)中R4代表氢或C1-C3烷基，n可以是3至5的整数。
• Novel 5-substituted derivatives of 2’-deoxy-6-azauridine with antibacterial activity
  作者：Sergey D. Negrya、Olga V. Efremenkova、Pavel N. Solyev、Vladimir O. Chekhov、Maxim A. Ivanov、Irina G. Sumarukova、Inna L. Karpenko、Sergey N. Kochetkov、Liudmila A. Alexandrova

  DOI：10.1038/s41429-019-0158-z

  日期：2019.7

  method for preparation of α- and β-anomers of 5-modified 6-aza- and 2-thio-6-aza-2'-deoxyuridine derivatives in high yields. 2-Thio derivatives demonstrated moderate activity against Mycobacterium smegmatis (MIC = 0.2-0.8 mM), Staphylococcus aureus (MIC = 0.03-0.9 mM) and some other Gram-positive bacteria. 2'-Deoxy-2-thio-5-phenyl-6-azauridine (2b) effectively suppressed the growth of Gram-negative bacteria

  新的耐药菌菌株的出现使得必须开发新的抗菌剂。新型抗菌剂之一是核苷类似物。我们已经开发出一种快速简单的一锅法，可高产率地制备5-修饰的6-aza-和2-thio-6-aza-2'-脱氧尿苷衍生物的α-和β-端基异构体。2-硫代衍生物对耻垢分枝杆菌（MIC = 0.2-0.8 mM），金黄色葡萄球菌（MIC = 0.03-0.9 mM）和其他一些革兰氏阳性细菌具有中等活性。2'-Deoxy-2-thio-5-phenyl-6-azauridine（2b）有效地抑制了革兰氏阴性细菌铜绿假单胞菌ATCC 27853（MIC = 0.03 mM）的生长，这种细菌由于高致病性而难以治疗对抗生素有抗药性。化合物2a，b和3a的5'-单磷酸盐，将b对接至结核分枝杆菌黄素依赖性胸苷酸合酶（ThyX）酶的结合位点。分子模型证明了5-修饰的2-硫代-6-氮杂-2'-脱氧尿苷5'-单磷酸结合在酶的活性位点内的可能性，从而抑制了细菌的生长。
• Comparative studies for selective deprotection of the N-arylideneamino moiety from heterocyclic amides: kinetic and theoretical studies. Part 2
  作者：Nouria A. Al-Awadi、Yehia A. Ibrahim、Hicham H. Dib、Maher R. Ibrahim、Boby J. George、Mariam R. Abdallah

  DOI：10.1016/j.tet.2006.04.054

  日期：2006.6

  synthesized and pyrolyzed in the gas phase. The kinetic effect of changing the substituent on the triazine ring from hydrogen to methyl, phenyl, and styryl was measured. Analyses of the pyrolyzates of 2–5 showed the elimination products to be benzonitrile and the triazine fragment, while the pyrolyzates of 6 and 7 reveal the formation of cis- and trans-cinnamonitriles. Theoretical study of the pyrolysis reactions

  4-苄基氨基-1,2,4-三嗪-3,5（2 ħ，4 ħ） -二酮（2 - 5），6-苯乙烯基-1,2,4-三嗪-3,5（2 ħ，4合成了H）-二酮（6）和6-苯乙烯基-2,3-二氢-3-硫代-1,2,4-三嗪-5（4 H）-一（7），并在气相中进行了热解。测量了将三嗪环上的取代基从氢变为甲基，苯基和苯乙烯基的动力学效果。对2 – 5的热解产物的分析表明，消除产物为苄腈和三嗪片段，而6和7的热解产物为揭示了顺式和反式肉桂腈的形成。使用从头开始的SCF方法对2 – 5的热解反应进行了理论研究。
• AZABICYCLO [3. 1. 0] HEXYL DERIVATIVES AS MODULATORS OF DOPAMINE D3 RECEPTORS
  申请人：Bertani Barbara

  公开号：US20100240661A1

  公开（公告）日：2010-09-23

  The present invention relates to novel compounds of formula (I) or a salt thereof: wherein G is selected from a group consisting of: phenyl, a 5- or 6-membered monocyclic heteroaryl group, or a 8- to 11-membered heteroaryl bicyclic group; p is an integer ranging from 0 to 5; R 1 is halogen, hydroxy, cyano, C 1-4 alkyl, haloC 1-4 alkyl, C 1-4 alkoxy, haloC 1-4 alkoxy, C 1-4 alkanoyl and SF 5 ; or corresponds to a group R 6 ; and when p is an integer ranging from 2 to 5, each R 1 may be the same or different; R 2 is hydrogen or C 1-4 alkyl; n is 3, 4, 5 or 6; R 6 is a moiety selected from the group consisting of: isoxazolyl, —CH 2 —N-pyrrolyl, 1,1-dioxido-2-isothiazolidinyl, thienyl, thiazolyl, pyridyl, 2-pyrrolidinonyl, and such R 6 group is optionally substituted by one or two substituents selected from: halogen, cyano, C 1-4 alkyl, haloC 1-4 alkyl, C 1-4 alkoxy, C 1-4 alkanoyl; R 4 is selected in the group consisting of: hydrogen, halogen, hydroxy, cyano, C 1-4 alkyl, C 3-7 cycloalkyl, haloC 1-4 alkyl, C 1-4 alkoxy, haloC 1-4 alkoxy, C 1-4 alkanoyl and NR′R″; or R 4 is a phenyl group, a 5-14 membered heterocyclic group; and any of such phenyl or heterocyclic group is optionally substituted by 1, 2, 3 or 4 substituents selected from the group consisting of: halogen, cyano, C 1-4 alkyl, haloC 1-4 alkyl, C 1-4 alkoxy, C 1-4 alkanoyl, haloC 1-4 alkoxy and SF 5 ; R 7 is hydrogen or C 1-2 alkyl; R′ is H, C 1-4 alkyl or C 1-4 alkanoyl; R″ is defined as R′; R′ and R″ taken together with the interconnecting nitrogen atom may form a 5-, 6-membered saturated or unsaturated heterocyclic ring; and their use in therapy, as modulators of dopamine D 3 receptors.

  本发明涉及一种式（I）的新化合物或其盐：其中G选自以下组中的一组：苯基，5-或6-成员的单环杂芳基团或8-至11-成员的杂芳双环基团；p为0至5的整数；R1为卤素，羟基，氰基，C1-4烷基，卤代C1-4烷基，C1-4烷氧基，卤代C1-4烷氧基，C1-4酰基和SF5；或对应于R6基团；当p是2至5的整数时，每个R1可以相同或不同；R2为氢或C1-4烷基；n为3、4、5或6；R6为选自以下组中的基团：异氧唑基，-CH2-N-吡咯基，1,1-二氧杂氮环戊基，噻吩基，噻唑基，吡啶基，2-吡咯烷基，且此类R6基团可以被选自以下一种或两种取代基取代：卤素，氰基，C1-4烷基，卤代C1-4烷基，C1-4烷氧基，C1-4酰基；R4选自以下组中的一种：氢，卤素，羟基，氰基，C1-4烷基，C3-7环烷基，卤代C1-4烷基，C1-4烷氧基，卤代C1-4烷氧基，C1-4酰基和NR′R″；或R4为苯基，5-14成员的杂环基团；此类苯基或杂环基团可以被1、2、3或4个选自以下组的取代基所取代：卤素，氰基，C1-4烷基，卤代C1-4烷基，C1-4烷氧基，C1-4酰基，卤代C1-4烷氧基和SF5；R7为氢或C1-2烷基；R′为H，C1-4烷基或C1-4酰基；R″被定义为R′；R′和R″与相互连接的氮原子一起可以形成5-，6-成员的饱和或不饱和杂环环；并且这些化合物可用于治疗，作为多巴胺D3受体的调节剂。